Enhanced systems and methods for RF-induced hyperthermia

• US 7,510,555 B2
• Filed: 02/03/2005
• Issued: 03/31/2009
• Est. Priority Date: 05/07/2004
• Status: Active Grant

• Current Assignee: NeoTherma Oncology, Inc.
• Original Assignee: Therm Med, LLC
• Inventors: Kanzius, John
• Primary Examiner(s): Johnson, III; Henry M
• Application Number:
  US11/050,422
• Publication Number:
  US 20060190063A1
• Time in Patent Office: 1,517 Days
• Field of Search: 128/898, 424 91- 94, 606 27- 52
• US Class Current: 606/33
• CPC Class Codes: A61N 1/406 using implantable thermoseeds or injected particles for localized hyperthermia preparations of seeds and particles A61K41/0052

Abstract

A method of inducing hyperthermia in at least a portion of a target area—e.g., a tumor or a portion of a tumor or targeted cancerous cells—is provided. Targeted RF absorption enhancers, e.g., antibodies bound to RF absorbing particles, are introduced into a patient. These targeted RF absorption enhancers will target certain cells in the target areas and enhance the effect of a hyperthermia generating RF signal directed toward the target area. The targeted RF absorption enhancers may, in a manner of speaking, add one or more RF absorption frequencies to cells in the target area, which will permit a hyperthermia generating RF signal at that frequency or frequencies to heat the targeted cells.

Claims

1. A method for killing or damaging target cells in a patient, comprising:

introducing into the patient RF absorption enhancers capable of selectively binding to the target cells and further capable of generating sufficient heat to kill or damage the bound target cells by heat generated solely by the application of an RF field generated by an RF signal between a transmission head and a reception head that is different from the transmission head;

arranging the transmission and reception heads on opposite sides of a portion of the patient for treatment; and

irradiating the portion of the patient between the transmission and reception heads containing RF absorption enhancers with an RF field to kill or damage the target cells from the heat generated by the RF absorption enhancers.

2. The method of claim 1, wherein the patient is irradiated with a field consisting essentially of an RF field between the transmission and reception heads.

3. The method of claim 1, wherein the patient is irradiated solely with an RF field between the transmission and reception heads.

4. The method of claim 1, wherein the RF absorption enhancers are excited to generate heat for killing or damaging the target cells by hyperthermia solely by irradiation with a field consisting essentially of an RF field between the transmission and reception heads.

5. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one electrically conductive particle.

6. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle of electrically conductive metal.

7. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive metal.

8. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle of electrically conductive gold.

9. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive gold.

10. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle that rectifies the RF signal, the at least one particle being small enough to be carried to a target cell via the patient'"'"'s vascular system.

11. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one tuned electronic circuit small enough to be carried to a target cell via the patient'"'"'s vascular system, wherein the at least one tuned electronic circuit has at least one particle frequency associated therewith, and further wherein the RF signal has at least one frequency corresponding to the at least one particle frequency.

12. The method according to claim 4 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one electrically conductive particle.

13. The method according to claim 4 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one particle of electrically conductive metal.

14. The method according to claim 4 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one nanoparticle of electrically conductive metal.

15. The method according to claim 4 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one particle of electrically conductive gold.

16. The method according to claim 4 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one nanoparticle of electrically conductive gold.

17. The method according to claim 4 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one electrically conductive particle.

18. The method according to claim 4 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one particle of electrically conductive metal.

19. The method according to claim 4 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one nanoparticle of electrically conductive metal.

20. The method according to claim 4 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one particle of electrically conductive gold.

21. The method according to claim 4 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one nanoparticle of electrically conductive gold.

22. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one electrically conductive nanoparticle.

23. The method according to claim 4 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive metal.

24. The method of claim 1, wherein the RF absorption enhancers are excited to generate heat for killing or damaging the target cells by hyperthermia solely by irradiation with an RF field between the transmission and reception heads.

25. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one electrically conductive particle.

26. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle of electrically conductive metal.

27. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive metal.

28. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle of electrically conductive gold.

29. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive gold.

30. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle that rectifies the RF signal, the at least one particle being small enough to be carried to a target cell via the patient'"'"'s vascular system.

31. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one tuned electronic circuit small enough to be carried to a target cell via the patient'"'"'s vascular system, wherein the at least one tuned electronic circuit has at least one particle frequency associated therewith, and further wherein the RF signal has at least one frequency corresponding to the at least one particle frequency.

32. The method according to claim 24 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one electrically conductive particle.

33. The method according to claim 24 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one particle of electrically conductive metal.

34. The method according to claim 24 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one nanoparticle of electrically conductive metal.

35. The method according to claim 24 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one particle of electrically conductive gold.

36. The method according to claim 24 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one nanoparticle of electrically conductive gold.

37. The method according to claim 24 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one electrically conductive particle.

38. The method according to claim 24 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one particle of electrically conductive metal.

39. The method according to claim 24 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one nanoparticle of electrically conductive metal.

40. The method according to claim 24 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one particle of electrically conductive gold.

41. The method according to claim 24 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one nanoparticle of electrically conductive gold.

42. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one electrically conductive nanoparticle.

43. The method according to claim 24 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive metal.

44. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one electrically conductive particle.

45. The method according to claim 44 wherein the RF absorption enhancers comprise at least one targeting moiety bound directly to at least one electrically conductive particle.

46. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle of electrically conductive metal.

47. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive metal.

48. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle of electrically conductive gold.

49. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive gold.

50. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one particle that rectifies the RF signal, the at least one particle being small enough to be carried to a target cell via the patient'"'"'s vascular system.

51. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one tuned electronic circuit small enough to be carried to a target cell via the patient'"'"'s vascular system, wherein the at least one tuned electronic circuit has at least one particle frequency associated therewith, and further wherein the RF signal has at least one frequency corresponding to the at least one particle frequency.

52. The method according to claim 1 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one electrically conductive particle.

53. The method according to claim 1 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one particle of electrically conductive metal.

54. The method according to claim 1 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one nanoparticle of electrically conductive metal.

55. The method according to claim 1 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one particle of electrically conductive gold.

56. The method according to claim 1 wherein the RF absorption enhancers comprise at least one biomolecule bound to at least one nanoparticle of electrically conductive gold.

57. The method according to claim 1 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one electrically conductive particle.

58. The method according to claim 1 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one particle of electrically conductive metal.

59. The method according to claim 1 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one nanoparticle of electrically conductive metal.

60. The method according to claim 1 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one particle of electrically conductive gold.

61. The method according to claim 1 wherein the RF absorption enhancers comprise at least one antibody or antibody fragment or other targeting moiety bound to at least one nanoparticle of electrically conductive gold.

62. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one electrically conductive nanoparticle.

63. The method according to claim 1 wherein the RF absorption enhancers comprise at least one targeting moiety bound to at least one nanoparticle of electrically conductive metal.

64. The method according to any of claim 1, claim 44, claim 46, claim 47, claim 48, claim 49, claim 50, claim 62, and claim 63 wherein the heating of the RF absorption enhancers is caused without a separate, external magnetic field to induce heating of the RF absorption enhancers by the RF signal.

65. The method according to any of claims 1-10, 22-24, 44, 46-50, 62 and 63, wherein the transmission head comprises a first electrically conductive plate insulated from the patient by at least an air gap and the reception head comprises a second electrically conductive plate insulated from the patient by at least an air gap, and an RF field is set up between the first and second electrically conductive plates for heating the RF absorption enhancers.

66. The method according to any of claims 1, 44, 46, 47, 48, 49, 50, 62, and 63 wherein the heating of the RF absorption enhancers is caused without a separate, external magnetic field to induce heating of the RF absorption enhancers by the RF signal, and further wherein the transmission head comprises a first electrically conductive plate insulated from the patient by at least an air gap and the reception head comprises a second electrically conductive plate insulated from the patient by at least an air gap, and an RF field is set up between the first and second electrically conductive plates for heating the RF absorption enhancers.

67. The method according to any of claims 1-10, 22-24, 44, 46-50, 62 and 63, wherein the RF signal comprises a signal having a frequency component at one of about 13.56 MHz and about 27.12 MHz for heating the RF absorption enhancers.

68. The method according to any of claims 1-10, 22-24, 44, 46-50, 62 and 63, wherein the RF signal is a frequency modulated (FM) RF signal having parameters selected to correspond to specific RF absorbing particles being used in the RF absorption enhancers.

69. The method according to claim 68 wherein the RF signal is a frequency modulated (FM) RF signal having a center frequency corresponding to a resonant frequency of a nominal RF absorbing particle being used in the RF absorption enhancers and the modulation of the FM RF signal corresponds to a range of a parameter of the RF absorbing particles being used in the RF absorption enhancers.

70. The method according to any of claims 1-10, 22-24, 44, 46-50, 62 and 63, wherein RF absorbing particles of the RF absorption enhancers have an associated manufacturing tolerance resulting in an associated range of resonant frequencies and further wherein the RF signal comprises a plurality of frequencies corresponding to the range of resonant frequencies associated with the manufacturing tolerance of the RF absorbing particles of the RF absorption enhancers.

71. The method according to any of claims 1-10, 22-24, 44, 46-50, 62 and 63, wherein the transmission head comprises a first electrically conductive plate insulated from the patient by at least an air gap and the reception head comprises a second electrically conductive plate insulated from the patient by at least an air gap, and an RF field is set up between the first and second electrically conductive plates for heating the RF absorption enhancers, and further wherein the RF signal comprises a signal having a frequency component at one of about 13.56 MHz and about 27.12 MHz for heating the RF absorption enhancers.

72. The method according to any of claims 1, 44, 46, 47, 48, 49, 50, 62, and 63 wherein the heating of the RF absorption enhancers is caused without a separate, external magnetic field to induce heating of the RF absorption enhancers by the RF signal, further wherein the transmission head comprises a first electrically conductive plate insulated from the patient by at least an air gap and the reception head comprises a second electrically conductive plate insulated from the patient by at least an air gap, and an RF field is set up between the first and second electrically conductive plates for heating the RF absorption enhancers, and further wherein the RF signal comprises a signal having a frequency component at one of about 13.56 MHz and about 27.12 MHz for heating the RF absorption enhancers.

73. The method according to any of claims 1, 44, 46, 47, 48, 49, 50, 62, and 63 wherein the wherein the step of introducing the RF absorption enhancers into the patient comprises injecting the RF absorption enhancers into the patient.